Cargando…

The use of long-acting Aripiprazole in a multi-center, prospective, uncontrolled, open-label, cohort study in Germany: a report on global assessment of functioning and the WHO wellbeing index

BACKGROUND: In this non-interventional study, the functionality and well-being of patients with schizophrenia with aripiprazole once-monthly (AOM) was evaluated under real-life conditions in a naturalistic population. METHODS: This non-interventional, prospective, multicenter 6-month study included...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schöttle, Daniel, Janetzky, Wolfgang, Luedecke, Daniel, Beck, Elmar, Correll, Christoph U., Wiedemann, Klaus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7035668/ https://www.ncbi.nlm.nih.gov/pubmed/32087718 http://dx.doi.org/10.1186/s12888-020-02488-1

Ejemplares similares

Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study
por: Schöttle, Daniel, et al.
Publicado: (2018)

Correction to: Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study
por: Schöttle, Daniel, et al.
Publicado: (2018)

BPRS domains, items and subgroups analyses, and CGI-I ratings in pooled data from non-interventional studies of aripiprazole once-monthly in schizophrenia (REACT study)
por: Schöttle, Daniel, et al.
Publicado: (2023)

Improvement of functioning in patients with schizophrenia: real-world effectiveness of aripiprazole once-monthly (REACT study)
por: Oluboka, Oloruntoba, et al.
Publicado: (2023)

Real-world effectiveness of aripiprazole once-monthly REACT study: Pooled analysis of two noninterventional studies
por: Schöttle, Daniel, et al.
Publicado: (2022)

Symptomatic, functional and quality of life measures of remission in 194 outpatients with schizophrenia followed naturalistically in a 6-month, non-interventional study of aripiprazole once-monthly
por: Correll, Christoph U., et al.
Publicado: (2023)

Reduction of Involuntary Admissions in Patients With Severe Psychotic Disorders Treated in the ACCESS Integrated Care Model Including Therapeutic Assertive Community Treatment
por: Schöttle, Daniel, et al.
Publicado: (2019)

Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia
por: Hattori, Saki, et al.
Publicado: (2023)

Use of Aripiprazole Long Acting Injection in Negative Symptoms of Schizophrenia
por: James, Suneeta, et al.
Publicado: (2016)

Biological conversion of aripiprazole lauroxil - An N-acyloxymethyl aripiprazole prodrug
por: Rohde, Morten, et al.
Publicado: (2014)

Plasma concentrations and dosing of 2 long-acting injectable formulations of aripiprazole
por: Salzman, Phyllis M, et al.
Publicado: (2017)

Corrigendum to “Use of Aripiprazole Long Acting Injection in Negative Symptoms of Schizophrenia”
por: James, Suneeta, et al.
Publicado: (2019)

Population Pharmacokinetic Analysis and Model-Based Simulations of Aripiprazole for a 1-Day Initiation Regimen for the Long-Acting Antipsychotic Aripiprazole Lauroxil
por: Hard, Marjie L., et al.
Publicado: (2018)

Pharmacokinetics and safety of deltoid or gluteal injection of aripiprazole lauroxil NanoCrystal(®) Dispersion used for initiation of the long-acting antipsychotic aripiprazole lauroxil
por: Hard, Marjie L., et al.
Publicado: (2019)

Aripiprazole Lauroxil: Pharmacokinetic Profile of This Long-Acting Injectable Antipsychotic in Persons With Schizophrenia
por: Hard, Marjie L., et al.
Publicado: (2017)

Aripiprazole Long-Acting Injection During First Episode Schizophrenia—An Exploratory Analysis
por: Giordano, Gloria, et al.
Publicado: (2020)

Acceptance of the Deltoid Muscle Injection of Aripiprazole Long-acting Injectable in the Patients with Schizophrenia
por: Kamei, Hiroyuki, et al.
Publicado: (2020)

Alternative starting regimen with aripiprazole long-acting treatments, a case report
por: Huete Naval, M., et al.
Publicado: (2022)

S206. ARIPIPRAZOLE LONG-ACTING INJECTABLE IN SCHIZOPHRENIA DURING PREGNANCY: A CASE REPORT
por: Sole, Eva, et al.
Publicado: (2020)

Long-acting injectable aripiprazole in pregnant women with schizophrenia: a case-series report
por: Fernández-Abascal, Blanca, et al.
Publicado: (2021)

Effectiveness of 2-year treatment with aripiprazole long-acting injectable and comparison with paliperidone palmitate
por: Mason, Katy, et al.
Publicado: (2021)

Effectiveness of Switching to Long-acting Injectable Aripiprazole in Patients with Recent-onset and Chronic Schizophrenia
por: Kim, Sung-Wan, et al.
Publicado: (2023)

Chlorine Atoms of an Aripiprazole Molecule Control the Geometry and Motion of Aripiprazole and Deschloro-aripiprazole in Subdomain IIIA of Human Serum Albumin
por: Kawai, Akito, et al.
Publicado: (2022)

Spotlight on once-monthly long-acting injectable aripiprazole and its potential as maintenance treatment for bipolar I disorder in adult patients
por: Torres-Llenza, Vanessa, et al.
Publicado: (2018)

Hospitalization rates and resource utilization of schizophrenic patients switched from oral antipsychotics to aripiprazole-depot in Germany
por: Potempa, Christoph, et al.
Publicado: (2018)

Efficacy and Safety of Aripiprazole for Treatment of Irritability in Children with Autistic Disorder: An Open-Label Study
por: Habibi, Nastaran, et al.
Publicado: (2015)

Effect of long-acting aripiprazole monohydrate on inpatient encounters: A retrospective mirror image study
por: Aguilar, Monica, et al.
Publicado: (2019)

Pharmacogenetic evaluation to assess breakthrough psychosis with aripiprazole long-acting injection: a case report
por: Eum, Seenae, et al.
Publicado: (2017)

Long-acting formulations delivering aripiprazole: beyond single-value characterizations of steady-state pharmacokinetics
por: McConnell, Scott A, et al.
Publicado: (2017)

Taiwan Expert Consensus Recommendations for Switching to Aripiprazole Long-Acting Once-Monthly in Patients with Schizophrenia
por: Liang, Chih-Sung, et al.
Publicado: (2021)

Effects of aripiprazole long-acting two-injection start in patients diagnosed with schizophrenia in Huelva (Spain)
por: Moleon, A., et al.
Publicado: (2023)

Aripiprazole cardiosafety: Is it overestimated?
por: Naguy, Ahmed
Publicado: (2016)

Aripiprazole-induced priapism
por: Trivedi, Satya K., et al.
Publicado: (2016)

TARC: Turkish aripiprazole consensus report- Aripiprazole use and switching from other antipsychotics to aripiprazole- consensus recommendations by a Turkish multidisciplinary panel
por: Veznedaroglu, Baybars, et al.
Publicado: (2018)

Open-label study comparing the efficacy and tolerability of aripiprazole and haloperidol in the treatment of pediatric tic disorders
por: Yoo, Hanik K., et al.
Publicado: (2010)

Use of long acting injectable aripiprazole before and through pregnancy in bipolar disorder: a case report
por: Ballester-Gracia, Isabel, et al.
Publicado: (2019)

Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate
por: Such, Pedro, et al.
Publicado: (2021)

Efficacy and tolerability Aripiprazole once-monthly long-acting injectable in schizophrenia. Two-injection start regimen
por: Romero Guillena, S.L., et al.
Publicado: (2022)

Mental Wellbeing and Social Resilience of Eritrean Refugees Living in Germany
por: Gebresilassie, Temesghen, et al.
Publicado: (2022)

Health Care Situation in the Treatment of Uncontrolled GINA Step 4/5 Patients in Germany
por: Timmermann, Hartmut, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_sbgfnjhjdk0g8o60b5bnbo7eha